Every Form 4 that Hinge Health, Inc. (HNGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HNGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HNGE filings page.
Hinge Health, Inc. CEO & Co-Founder, director and ten percent owner Daniel Antonio Perez converted 4,100 Class B shares into 4,100 Class A shares on October 6, 2026, then sold 4,100 Class A shares at a weighted average $100.1978 per share. The sale was made under a Rule 10b5-1 plan adopted by Perez and his spouse on June 11, 2026. Following the transaction, Perez reported 9,774,572 Class B shares, excluding 3,777,002 performance-based restricted stock units. His spouse separately held 208,445 Class B shares and 35,470 Class A shares indirectly.
Hinge Health, Inc. (HNGE) director Tyler Sloat received 175 shares of Class A common stock on October 5, 2026, upon settlement of fully vested restricted stock units. The reported per-share price was $92.5620. The RSUs were awarded in lieu of quarterly cash retainers, at Sloat’s election, under the company’s Non-Employee Director Compensation Program. He directly held 10,385 shares after the transaction.
Hinge Health, Inc. (HNGE) President James Pursley relinquished and had 831 shares of Class A Common Stock cancelled on October 1, 2026, in connection with federal and state tax withholding obligations from restricted stock unit vesting. In exchange, the company agreed to pay those obligations. Pursley reported 666,078 shares held directly after the transaction.
Hinge Health, Inc. Chief Financial Officer James Budge relinquished 4,614 Class A shares on October 1, 2026. The issuer canceled the shares in exchange for agreeing to pay federal and state tax withholding obligations resulting from restricted stock unit vesting. The reported price was $97.24 per share; Budge held 344,448 shares directly after the transaction.
Hinge Health, Inc. President James Pursley reported three sales of Class A Common Stock on September 21, 2026: 9,065 shares at a weighted average sale price of $93.3680 per share, 23,135 shares at a weighted average sale price of $94.4044 per share, and 800 shares at a weighted average sale price of $95.0968 per share. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2026.
Hinge Health, Inc. (HNGE) director Robinson Elliott reported a sale of Class A Common Stock on September 14, 2026, carried out by affiliated Bessemer Venture Partners funds. Bessemer Venture Partners X L.P. sold 76,306 shares and Bessemer Venture Partners X Institutional L.P. sold 71,632 shares at a weighted average price of $93.53, in multiple trades between $92.71 and $93.64. Elliott has an indirect, passive economic interest through partnership interests in the Bessemer funds and disclaims beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 trading plan is reported.
Hinge Health, Inc. director and executive chairman Gabriel M.I. Mecklenburg reported converting 150,000 shares of Class B Common Stock into 150,000 shares of Class A Common Stock on September 14, 2026, and selling 150,000 Class A shares in multiple open-market transactions on the same date under a Rule 10b5-1 trading plan adopted on June 12, 2026. The sales occurred at weighted-average prices ranging from the high‑$80s to mid‑$90s per share. After these transactions, he held 1,844,004 Class B shares directly, plus additional Class B shares held indirectly through a family trust and a grantor retained annuity trust, each convertible into Class A on a one‑for‑one basis or as otherwise stated.
Hinge Health, Inc. (HNGE) director and executive chairman Gabriel M.I. Mecklenburg converted 250,000 shares of Class B Common Stock into Class A Common Stock on September 11, 2026, then sold 250,000 Class A shares in multiple open-market trades at weighted average prices within $86.35–$90.61. The sales were effected under a Rule 10b5-1 trading plan adopted on June 12, 2026. Following the conversion, he held 1,944,004 Class B shares directly and additional Class B shares indirectly through a family trust and a GRAT, representing 383,592 and 857,880 underlying Class A shares, respectively.
Hinge Health, Inc. (HNGE) reported that Chief Financial Officer James Budge sold a total of 55,561 shares of Class A common stock on September 10, 2026, in multiple open-market transactions at weighted average prices ranging from about $88.22 to $91.62. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by James Budge and his spouse on June 11, 2026.
Hinge Health, Inc. (HNGE) reported that CEO, co‑founder and major shareholder Daniel Antonio Perez and his spouse converted a total of 295,000 shares of Class B Common Stock into Class A Common Stock on September 10, 2026, then disposed of 250,000 Class A shares through open‑market sales and transferred 45,000 Class A shares as a bona fide gift. The sales were made under a Rule 10b5‑1 trading plan adopted on June 11, 2026, and Perez continued to hold 9,778,672 Class B shares directly and 208,445 Class B shares indirectly through his spouse after the reported conversions, excluding 3,777,002 performance‑based restricted stock units.
Hinge Health, Inc. (HNGE) reported that investment funds associated with director Robinson Elliott sold shares of its Class A Common Stock on September 9, 2026.
Bessemer Venture Partners X L.P. sold 5,489 shares and Bessemer Venture Partners X Institutional L.P. sold 5,848 shares at a weighted average price of $92.37, in multiple trades between $92.00 and $92.69. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these shares and disclaims beneficial ownership except to the extent of any pecuniary interest.
Hinge Health, Inc. (HNGE) director Robinson Elliott reported two indirect sales of Class A Common Stock associated with Bessemer venture funds. On September 4, 2026, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. sold 7,450 and 6,994 shares, respectively, at a weighted average price of $92.17. On September 8, 2026, the same funds sold 21,006 and 19,719 shares, respectively, at a weighted average price of $92.58. The shares were sold in multiple transactions within disclosed price ranges, and Elliott disclaims beneficial ownership except for any indirect pecuniary interest.
Hinge Health, Inc. (HNGE) director-affiliated funds reported open-market sales of the company’s Class A Common Stock in early September 2026. On September 2, Bessemer Venture Partners X L.P. sold 35,918 shares and Bessemer Venture Partners X Institutional L.P. sold 33,717 shares at a weighted average price of $93.01 per share, in multiple trades between $92.72 and $93.52.
On September 3, 2026, the same funds sold 516 and 484 shares, respectively, at a weighted average price of $92.64 per share, in trades between $92.05 and $92.99. Reporting person Robinson Elliott, a partner at Bessemer Venture Partners, has an indirect, passive economic interest and disclaims beneficial ownership beyond any pecuniary interest.
Hinge Health, Inc. (HNGE) reported that President James Pursley had 6,326 shares of Class A Common Stock withheld on September 1, 2026 to satisfy federal and state tax withholding obligations arising from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e).
The shares were relinquished and cancelled in exchange for the issuer paying these taxes, leaving Pursley with 699,909 shares held directly after the transaction; no Rule 10b5-1 trading plan is reported.
Hinge Health, Inc. (HNGE) reported that Chief Financial Officer James Budge had 9,986 shares of Class A Common Stock withheld on September 1, 2026 to cover exercise price or tax liabilities related to vesting restricted stock units. The shares were relinquished and cancelled in exchange for the company paying his federal and state tax withholding obligations, leaving him with 404,623 shares held directly. No Rule 10b5-1 trading plan is reported.
Hinge Health, Inc. (HNGE) reported that entities affiliated with Bessemer Venture Partners sold shares of its Class A Common Stock. On August 25, 2026, Bessemer Venture Partners X L.P. and Bessemer Venture Partners X Institutional L.P. sold shares at a weighted average price of $91.08, and on August 26, 2026 they sold additional shares at a weighted average price of $91.71. Reporting person Robinson Elliott is a partner at Bessemer Venture Partners and has only an indirect, passive economic interest in these securities and disclaims beneficial ownership except to the extent of any pecuniary interest.
Hinge Health, Inc. (HNGE) reported that its Chief Financial Officer, James Budge, made a bona fide gift of 11,563 shares of Class A Common Stock on 2026-08-24. After this gift, he directly holds 414,609 shares of Class A Common Stock.
Hinge Health, Inc. (HNGE) reported that President James Pursley sold a total of 33,000 shares of Class A Common Stock on August 21, 2026, in multiple open-market transactions under a Rule 10b5-1 trading plan adopted on June 13, 2025. The reported weighted average sale prices ranged from about $84.80 to $88.68 per share across the four tranches.
Hinge Health, Inc. (HNGE) reported that director Leslie Kristina M sold Class A Common Stock. On 2026-08-20, the reporting person executed an open-market or private sale of 1,200 shares of Class A Common Stock at a price of $88.23 per share. Following this transaction, the director directly holds 30,387 shares of Class A Common Stock.
Hinge Health, Inc. (HNGE) had a Form 4 filed for reporting person Robinson Elliott in connection with sales of its Class A Common Stock by affiliated investment funds. On August 19, 2026, Bessemer Venture Partners X L.P. sold 13,527 shares and Bessemer Venture Partners X Institutional L.P. sold 12,699 shares at a weighted average price of $90.05 per share in multiple transactions between $90.00 and $90.44. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in the Bessemer Funds and expressly disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Hinge Health, Inc. director Teddie Benjamin Wardi reported an indirect acquisition of 4,637 shares of Class A Common Stock. The shares were received by Ingentorsk (Delaware) LLC through distributions from Insight Venture Associates X, L.P. and Insight Venture Partners X (Class A), L.P., with no consideration paid. Wardi controls Ingentorsk and may be deemed the beneficial owner of these securities under Rule 16a-1.
Hinge Health, Inc. director and Exec. Chairman & Co-Founder Gabriel M.I. Mecklenburg settled 944,250 performance-based restricted stock units (PSUs) into an equal number of shares of Class B Common Stock on August 4, 2026, after the PSUs vested upon certified performance achievement on July 27, 2026. To satisfy federal and state tax withholding obligations from this vesting, 509,423 Class B shares were relinquished and cancelled in exchange for the issuer covering those taxes, at a reference price of $77.65 per share, rather than being sold in the market. He retains indirect exposure to Class B Common Stock convertible 1:1 into Class A through entities holding 857,880 and 383,592 underlying shares via a GRAT and a family trust, respectively.
Hinge Health, Inc. reported that President James Pursley had 831 shares of Class A common stock withheld and cancelled on August 1, 2026 at $74.71 per share to satisfy federal and state tax withholding from vested restricted stock units, in an exempt Section 16b-3(e) transaction. Following this disposition, he directly holds 739,235 shares of Class A common stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported a single exempt transaction involving Class A Common Stock. On 2026-08-01, 4,614 shares were relinquished and cancelled at $74.71 per share to satisfy federal and state tax withholding obligations arising from the vesting of restricted stock units. Following this tax-withholding disposition, he holds 426,172 shares of Class A Common Stock directly. The transaction is exempt under Section 16b-3(e) and reflects payment of tax liabilities rather than an open-market sale.
Mecklenburg Gabriel M.I. reported acquisition or exercise transactions in this Form 4 filing.
Hinge Health, Inc. reported that executive chairman and co‑founder Gabriel M.I. Mecklenburg received a grant of 944,250 performance‑based restricted stock units. Each unit represents a contingent right to one share of Class B Common Stock, earned and vested on July 27, 2026 after certified performance criteria, with settlement deferred. The PSUs do not expire; they either vest or are cancelled prior to the vesting date.
Hinge Health, Inc. CEO and Co‑Founder Daniel Antonio Perez reported the vesting of 944,250 performance‑based restricted stock units on July 27, 2026, settling into Class B Common Stock. He relinquished 509,423 Class B shares at $74.3100 per share to cover tax withholding, and holds awards including 3,777,002 PSUs and 358,445 Class B shares held indirectly through his spouse.
Insight Holdings Group, LLC and affiliated Insight Venture funds, as ten percent owners of Hinge Health, Inc., reported a coordinated sequence of derivative conversions and open-market sales of Class A Common Stock on July 7 and July 9, 2026. The group converted derivative positions into an aggregate 426,171 Class A shares and sold the same number of shares in open-market transactions at prices around $90–$91 per share, according to the transaction data. The transactions are reported as indirect holdings, with further ownership details referenced in Exhibit 99.1.
Hinge Health, Inc. director Tyler Sloat acquired 246 shares of Class A Common Stock through the settlement of fully vested restricted stock units on July 5, 2026. These RSUs were granted in lieu of quarterly cash retainers under the company’s Non-Employee Director Compensation Program.
Following this equity grant, Sloat directly holds 10,210 shares of Class A Common Stock. This is a routine, compensation-related award rather than an open-market stock purchase or sale.
Hinge Health, Inc. Chief Financial Officer James Budge reported a routine tax-related share disposition. A total of 4,614 shares of Class A Common Stock were relinquished and cancelled to satisfy federal and state tax withholding from the vesting of restricted stock units, in an exempt transaction under Section 16b-3(e). Following this tax-withholding event, Budge directly holds 430,786 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. President James Pursley reported a small, exempt tax-withholding transaction involving 831 shares of Class A Common Stock. These shares were relinquished and cancelled so the company could pay his federal and state tax obligations arising from the vesting of restricted stock units, as permitted under Section 16b-3(e). Following this non-market disposition, Pursley directly holds 740,066 shares of Class A Common Stock.
Hinge Health, Inc. director and Executive Chairman & Co‑Founder Gabriel M.I. Mecklenburg reported an exercise‑and‑sell transaction involving 83,334 shares of Class A Common Stock. He converted 83,334 shares of Class B Common Stock into the same number of Class A shares and then sold 83,334 Class A shares in multiple open‑market trades.
The sales, executed at prices ranging from about $82.38 to $86.58 per share, were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. After these transactions, Mecklenburg continues to hold significant exposure through direct Class B holdings and indirect interests via a family trust and a GRAT that are convertible into Class A shares.
Hinge Health, Inc. disclosed that investment entities affiliated with Insight, reported as ten percent owners, completed a large convert-and-sell transaction in the company’s Class A Common Stock. They converted 1,466,667 Class B shares into Class A and then sold the same number in multiple open-market trades at prices between roughly $81.31 and $84.59 per share, resulting in a net sale of 1,466,667 shares and no remaining derivative position from this block.
Hinge Health, Inc. reported that investment entities affiliated with Insight, each a ten percent owner, executed a series of transactions in Class A and Class B Common Stock. On June 25, 2026, they sold an aggregate 530,982 shares of Class A Common Stock in multiple open-market sales at prices between $71.5879 and $73.1935 per share, all reported as indirect ownership. On the same date, they also converted derivative positions in Class B Common Stock into a matching 530,982 underlying Class A shares, with no remaining derivative positions shown after these conversions. The filing attributes these holdings and transactions to the Insight-affiliated funds referenced in the footnotes.
Hinge Health, Inc. disclosed that investment entities associated with Insight Venture Partners reported open-market sales of Class A Common Stock. On June 24, 2026, these entities sold a combined 142,311 shares at a reported price of $71.6669 per share through indirect ownership accounts. The Form 4 indicates these particular indirect positions now report zero shares following the transactions, and there are no remaining derivative securities listed in this filing.
Hinge Health, Inc. disclosed that Insight-affiliated investment entities, all reported as ten-percent owners, carried out a series of conversions and open‑market sales involving its Class A and Class B common stock. Over June 22–24, the entities converted a total of 870,104 Class B shares into Class A through derivative conversions coded "C" at a stated conversion price of $0.00 per share.
Across the same dates, they executed 727,793 Class A shares of open‑market sales (code "S") at prices generally around $70–$72 per share, including transactions at $71.6669, $71.1994, $70.8361 and $70.2145. Several non‑derivative transaction lines show zero Class A shares remaining after specific sale blocks, while related derivative entries show that Insight-controlled entities continue to hold indirect positions of Class B common stock in the millions of shares following these conversions.
Hinge Health, Inc. President James Pursley sold 33,000 shares of Class A Common Stock in open-market transactions. The sales occurred on June 22, 2026 across three trades at weighted average prices of $68.93, $69.82 and $70.89 per share.
The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 13, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Hinge Health, Inc. large shareholder entities affiliated with Insight reported a combination of share conversions and sales. On June 16, 2026, they converted an aggregate 65,581 shares of Class B Common Stock into Class A Common Stock, then executed open-market sales of 65,581 Class A shares at an average price of $70.3596 per share through indirect holdings noted in the footnotes. Following these transactions, the reported Class A positions in the sale lines were reduced to zero, while significant Class B Common Stock positions remained outstanding as derivative securities.
Hinge Health, Inc. reported June transactions in which Bessemer Venture Partners funds sold Class A Common Stock. On June 10, 2026, Bessemer Venture Partners X L.P. sold 15,619 shares and Bessemer Venture Partners X Institutional L.P. sold 14,662 shares at a weighted average price of $65.20, in multiple trades between $65.00 and $65.88. On June 11, 2026, the same funds sold 30,042 and 28,201 shares, respectively, at a weighted average price of $66.02, with prices from $65.55 to $66.45. On June 12, 2026, they sold 8,694 and 8,161 shares, respectively, at a weighted average price of $65.24, in trades between $65.00 and $66.00. Director Robinson Elliott is a partner at Bessemer Venture Partners and reports an indirect, passive economic interest in these holdings and expressly disclaims beneficial ownership except to the extent of any pecuniary interest.
Hinge Health, Inc. executive chairman and co‑founder Gabriel M.I. Mecklenburg reported an exercise‑and‑sell style transaction involving the company’s dual‑class shares. He converted 50,000 shares of Class B common stock into Class A common stock and then sold 50,000 Class A shares in open‑market transactions.
The weighted average sale price was about $65.53 per share, with individual trades ranging from $65.00 to $65.92, executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. Following the sales, he reported no directly held Class A shares, while continuing to hold substantial Class B interests directly and indirectly through a family trust and a GRAT, each convertible one‑for‑one into Class A shares. The filing also notes 944,250 performance stock units held by the reporting person are excluded from these share counts.
Hinge Health, Inc. director Leslie Kristina M received an equity compensation award in the form of restricted stock units. On June 3, 2026, she was granted 3,837 shares of Class A Common Stock at a reference value of $52.12 per share.
The award consists of 3,837 restricted stock units (RSUs) issued under the company’s Non-Employee Director Compensation Program for board service. These RSUs vest according to the award’s terms, and each RSU converts into one share of Class A Common Stock upon settlement. Following this grant, Leslie Kristina M directly owns 31,587 shares of Class A Common Stock.
Hinge Health, Inc. director Robinson Elliott filed a Form 4 reporting open-market sales of Class A Common Stock by funds affiliated with Bessemer Venture Partners. On June 1, 2026, Bessemer Venture Partners X L.P. sold 51,580 shares and Bessemer Venture Partners X Institutional L.P. sold 48,420 shares at a weighted average price of $61.08, executed in multiple trades between $60.82 and $61.44. On June 2, 2026, the same funds sold 10,121 and 9,500 shares, respectively, at a weighted average price of $60.34, in trades between $60.00 and $60.74. Elliott is a partner at Bessemer Venture Partners and has an indirect, passive economic interest in these holdings and expressly disclaims beneficial ownership beyond any indirect pecuniary interest.
Hinge Health, Inc. executive chairman and co-founder Gabriel M.I. Mecklenburg reported mixed insider activity that combines a derivative conversion with open-market sales of Class A Common Stock. On June 1, 2026, he converted 83,334 shares of Class B Common Stock into the same number of Class A shares and then sold 83,334 Class A shares in multiple open-market trades under a pre-arranged Rule 10b5-1 trading plan. The reported sale prices ranged from the mid‑$50s to low‑$60s per share, including trades around $55.21 to $62.07. Following these transactions, he held 83,334 Class A shares directly, along with indirect holdings of Class B Common Stock through a family trust and a GRAT that are convertible into 383,592 and 857,880 Class A shares, respectively.
Hinge Health, Inc. Chief Financial Officer James Budge reported a routine tax-withholding transaction involving 9,986 shares of Class A common stock at $56.21 per share. These shares were relinquished and cancelled so the company could cover his federal and state tax obligations from vesting restricted stock units. Following this disposition, he directly holds 435,400 shares of Class A common stock.
Hinge Health, Inc. President James Pursley reported a tax-related share withholding. On the transaction date, 6,326 shares of Class A Common Stock were relinquished at a value of $56.21 per share to cover federal and state tax withholding from the vesting of restricted stock units. These shares were cancelled by the company, which agreed to satisfy the tax obligations. After this exempt disposition, Pursley directly holds 773,897 shares, so his overall ownership remains substantial and the event reflects a routine, non-market transaction rather than an open-market sale.
Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 5,907 shares of the company’s Class A Common Stock on May 26, 2026. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
The sales occurred in three tranches: 3,507 shares at a weighted average price of $53.3237, 2,100 shares at $54.3733, and 300 shares at $55.2233. All reported holdings are direct, and no option exercises or derivative transactions are included in this filing.
Hinge Health, Inc. president James Pursley reported selling a total of 16,000 shares of Class A Common Stock in open-market transactions. The sales occurred on May 26, 2026 at weighted average prices of about $53–$55 per share, with individual trades recorded at $53.29, $54.29 and $55.16.
After these transactions, Pursley directly holds 780,223 shares. A footnote explains that at least one line of sales was effected under a Rule 10b5-1 trading plan adopted on June 13, 2025, and that his holdings include 781 shares acquired on May 15, 2026 through the company’s employee stock purchase plan.
Hinge Health director and Executive Chairman Gabriel Mecklenburg reported a planned mix of sales and conversions of Hinge Health, Inc. stock. On May 26, 2026, he sold a total of 83,333 shares of Class A Common Stock in open-market transactions at weighted average prices in the mid‑$50 range under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. These sales were paired with the conversion of 83,333 shares of Class B Common Stock into Class A Common Stock. After these transactions, he continues to hold a substantial stake through 1,860,675 shares of Class B Common Stock directly, plus additional Class B holdings equivalent to 383,592 and 857,880 underlying Class A shares through a family trust and a GRAT, respectively, as well as 944,250 performance stock units that are noted but excluded from the share totals.
Hinge Health, Inc. Chief Financial Officer James Budge sold 781 shares of Class A Common Stock in an open-market transaction at $55.34 per share on May 20, 2026. After this sale, he directly holds 451,293 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and his holdings include shares issued through the company’s employee stock purchase plan.
Hinge Health, Inc. President James Pursley received a grant of 65,000 shares of Class A Common Stock on April 29, 2026 through a restricted stock unit (RSU) award. The RSUs were granted for no cash consideration and each RSU converts into one share upon vesting. Following this award, Pursley directly holds 795,442 shares of Class A Common Stock reported in this filing.
Hinge Health, Inc. reported that Chief Financial Officer James Budge received an award of 65,000 shares of Class A Common Stock in the form of restricted stock units. The RSU grant was acquired for no cash consideration and brings his directly held stake to 451,293 shares.